Early research (Phase 1)Ended earlyNCT04762602What this trial is testingHMPL-306 in Advanced Solid Tumors With IDH MutationsWho this might be right forIsocitrate Dehydrogenase Gene Mutation Hutchmed 42
Testing effectiveness (Phase 2)Active Not RecruitingNCT05836571What this trial is testingTesting Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue SarcomaWho this might be right forLocally Advanced Extraskeletal Myxoid ChondrosarcomaLocally Advanced LeiomyosarcomaLocally Advanced Liposarcoma+7 more National Cancer Institute LAO 66
Testing effectiveness (Phase 2)Study completedNCT00474994What this trial is testingSunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent SarcomasWho this might be right forAdult Malignant Fibrous Histiocytoma of BoneDesmoid TumorEndometrial Cancer+3 more Memorial Sloan Kettering Cancer Center 53
Early research (Phase 1)Study completedNCT00720174What this trial is testingCixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaWho this might be right forAdult AngiosarcomaAdult Desmoplastic Small Round Cell TumorAdult Epithelioid Sarcoma+32 more National Cancer Institute (NCI) 30
Early research (Phase 1)Ended earlyNCT05355753What this trial is testingAssess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null TumorsWho this might be right forSynovial SarcomaSoft Tissue Sarcoma C4 Therapeutics, Inc. 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT04278781What this trial is testingAG-120 in People With IDH1 Mutant ChondrosarcomaWho this might be right forChondrosarcomaChondrosarcoma, Grade 2Chondrosarcoma, Grade 3+1 more Memorial Sloan Kettering Cancer Center 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT04340843What this trial is testingTesting the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaWho this might be right forLocally Advanced Unresectable Primary Central ChondrosarcomaMetastatic Primary Central ChondrosarcomaUnresectable Primary Central Chondrosarcoma National Cancer Institute (NCI) 19
Testing effectiveness (Phase 2)Looking for participantsNCT06176989What this trial is testingEnasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base TumorsWho this might be right forMetastatic ChondrosarcomaLocally Advanced ChondrosarcomaMetastatic Sinonasal Adenocarcinoma+7 more National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT02066285What this trial is testingTrial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaWho this might be right forSolitary Fibrous TumorExtraskeletal Myxoid Chondrosarcoma Grupo Espanol de Investigacion en Sarcomas 96
Testing effectiveness (Phase 2)Study completedNCT01310816What this trial is testingA Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) ChondrosarcomaWho this might be right forConventional Chondrosarcoma Infinity Pharmaceuticals, Inc. 105
Large-scale testing (Phase 3)Looking for participantsNCT06127407What this trial is testingIvosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment RegimenWho this might be right forLocally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen Servier Bio-Innovation LLC 136
Testing effectiveness (Phase 2)Active Not RecruitingNCT01267955What this trial is testingVismodegib in Treating Patients With Advanced ChondrosarcomasWho this might be right forClear Cell ChondrosarcomaDedifferentiated ChondrosarcomaLocally Advanced Chondrosarcoma+4 more National Cancer Institute (NCI) 45